

Section 1: Issuer information				
Name of issuer	AFT Pharmaceuticals Limited ("AFT")			
Financial product name/description	Final Dividend			
NZX ticker code	AFT			
ISIN (If unknown, check on NZX website)	NZAFTE0001S4			
Type of distribution (Please mark with an X in the relevant box/es)	Full Year	X	Quarterly	
	Half Year		Special	
	DRP applies			
Record date	20/06/2025			
Ex-Date (one business day before the Record Date)	19/06/2025			
Payment date (and allotment date for DRP)	04/07/2025			
Total monies associated with the distribution	\$1,887,593			
Source of distribution	Retained earnings and Income available for distribution			
Currency	NZD			
Section 2: Distribution amounts per financial product				
Gross distribution ¹	\$0.01800000			
Gross taxable amount ²	\$0.01800000			
Total cash distribution ³	\$0.01800000			
Excluded amount (applicable to listed PIEs)	N/A			
Supplementary distribution amount	N/A			
Section 3: Imputation credits and Resident Withholding Tax ⁴				
Is the distribution imputed	No imputation			
If fully or partially imputed, please state imputation rate as % applied	N/A			

¹ "Gross distribution" is the total cash distribution plus the amount of imputation credits, per financial product, before the deduction of Resident Withholding Tax (RWT).

² "Gross taxable amount" is the gross distribution minus any excluded income.

³ "Total cash distribution" is the cash distribution excluding imputation credits, per financial product, before the deduction of RWT. This should *include* any excluded amounts, where applicable to listed PIEs.

⁴ The imputation credits plus the RWT amount is 33% of the gross taxable amount for the purposes of this form. If the distribution is fully imputed the imputation credits will be 28% of the gross taxable amount with remaining 5% being RWT. This does not constitute advice as to whether or not RWT needs to be withheld.

Imputation tax credits per financial product	N/A
Resident Withholding Tax per financial product	\$0.00594000
Section 4: Distribution re-investment plan (if applicable)	
Not applicable	
Section 5: Authority for this announcement	
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby
Contact phone number	+64 9 488 0232
Contact email address	malcolm.tubby@aftpharm.com
Date of release through MAP	22/05/2025